IgniteData has announced a partnership with AstraZeneca and Memorial Sloan Kettering Cancer Center (MSK) for launching the Archer tool for automation of electronic health record (EHR)-to-electronic data capture (EDC) in a Phase III trial at MSK.
This initiative comes after a pilot programme, and it showcases the tool’s ability to streamline trials by enhancing accuracy and speed.
Go deeper with GlobalData
By the secure transfer of data from hospital EHRs directly to sponsor EDCs, the Archer platform removes the necessity for manually entering the data.
This automation allows data to be gathered more swiftly and with minimal errors, enabling researchers to dedicate extra time to progressing clinical science while upholding subject privacy and data integrity.
MSK Clinical Research Information Technology senior director Joe Lengfellner said: “The IgniteData Archer platform continues to improve the speed and quality of our data collection across clinical trials.
“The implementation of Archer in this AstraZeneca-sponsored Phase III study demonstrates the growing industry-academia alignment on the future of trial data management. This convergence will accelerate trial execution and improve data quality across the clinical research ecosystem.”
Archer serves as a Virtual Research Assistant. For researchers, the platform is found to be a ‘simple interface’, and its regulatory-grade mapping engine manages complex data integrations.
IgniteData chief operating officer Richard Yeatman said: “Our EHR-to-EDC automation technology is revolutionising how clinical trials are conducted.
“By reducing manual processes and ensuring data quality, we’re empowering research teams to deliver life-saving treatments more efficiently. This deployment is another step toward transforming the clinical trial landscape.”
IgniteData is focused on expanding its EHR-to-EDC automation across international research sites, aiming to enhance trial innovation.
Every deployment of the platform is intended to provide insights that refine the technology, with the goal of delivering precise clinical trial outcomes.
